Physician profile
Osman Ozel
NPI 1750901872
$2,415.44
in general payments reported to CMS, 2019-2025
20 companies · $519 in 2025
The $519 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $224 · 2023: $552 · 2024: $1,120 · 2025: $519.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,550 · Education: $89.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,550.39 |
| Education | $89.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $232.24 | 2024-2025 | Rystiggo, Briviact, Fintepla |
| Alexion Pharmaceuticals, INC. | $222.68 | 2024 | Ultomiris |
| Abbvie INC. | $184.88 | 2024-2025 | |
| Acadia Pharmaceuticals INC | $131.20 | 2024-2025 | Nuplazid, Daybue |
| Novartis Pharmaceuticals Corporation | $119.85 | 2024-2025 | |
| Janssen Biotech, INC. | $108.60 | 2025 | |
| Biogen, INC. | $101.70 | 2024-2025 | Spinraza, Tysabri, Vumerity |
| Csl Behring | $93.08 | 2024-2025 | Hizentra |
| Astrazeneca Pharmaceuticals LP | $90.92 | 2024 | Andexxa |
| Takeda Pharmaceuticals U.S.A., INC. | $79.97 | 2024 | Hyqvia |
| Argenx US, INC. | $66.61 | 2024-2025 | Vyvgart Hytrulo, Vyvgart |
| Impel Pharmaceuticals LLC | $40.13 | 2025 | Trudhesa |
| Tanabe Pharma America, INC. | $29.66 | 2024 | |
| Eisai INC. | $27.21 | 2024 | |
| Catalyst Pharmaceuticals, INC. | $24.39 | 2024 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $20.11 | 2024 | |
| Merz Pharmaceuticals, LLC | $18.82 | 2025 | Inbrija, Xeomin |
| Teva Pharmaceuticals USA, INC. | $18.49 | 2025 | Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $15.32 | 2024 | Nuedexta |
| Ge Healthcare | $13.53 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Osman Ozel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.